Zealand Pharma Reported Weight Loss Trial Results
The clinical trial for petrelintide showed a 10.7% body weight reduction in adults with obesity or overweight.
Updated on Sept. 29, 2026 in Weight Loss
Live Poll
Would you consider using a new prescription medication for weight management if your doctor recommended it?
Zealand Pharma has published Phase 2 trial results in The Lancet Diabetes & Endocrinology for its human amylin analog, petrelintide. The drug achieved weight loss of up to 10.7% over 42 weeks of treatment.
Why it matters
This study evaluated petrelintide as a potential therapeutic option for chronic weight management. The trial focused on its efficacy and safety profile in adults struggling with obesity or overweight.
The ZUPREME-1 trial enrolled 485 adults across 32 sites globally. Participants received once-weekly subcutaneous injections of petrelintide over the course of 42 weeks.
The players
Zealand Pharma
A biotechnology company headquartered in Copenhagen, Denmark, that focuses on the discovery and development of peptide-based medicines.
The details
The trial utilized a dose-finding design to evaluate the amylin analog across five different dosage levels. Gastrointestinal adverse events were reported at rates comparable to those observed in the placebo group.
Timeline
Final body weight measurements were recorded at week 42.
Additional trial results are scheduled for presentation on September 30, 2026, at EASD 2026.
Health Landscape
This study represents an expansion of the pharmaceutical industry's efforts to develop diverse peptide-based treatments for weight management beyond current GLP-1 options. The research marks a pivot toward amylin analogs as the search for new obesity therapeutics intensifies globally.
The results demonstrate the potential for a new once-weekly treatment option for individuals managing obesity. As the drug moves into a Phase 3 registrational program, patients may eventually have access to more varied classes of weight management medications.
The takeaway
The study highlights the potential of human amylin analogs in clinical weight management. Patients and healthcare providers should monitor future Phase 3 updates to track the long-term safety and efficacy of this treatment class.
What happens next
Zealand Pharma will present additional findings from the ZUPREME-1 trial at the EASD 2026 conference on September 30, 2026. Furthermore, the company plans to initiate a new Phase 2 trial for a combination therapy in the second half of 2026.
Further reading
For more on the developing field of pharmaceutical interventions, see our Weight Loss section.
Live Poll
Would you consider using a new prescription medication for weight management if your doctor recommended it?
